A detailed history of Capital Performance Advisors LLP transactions in Immunic, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 21 shares of IMUX stock, worth $24. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Holding current value
$24
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$1.08 - $1.95 $22 - $40
21 New
21 $0

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $36.4M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.